Celularity Inc (CELU) stock
CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.68−0.07 (-8.81%)
Close on Nov 12, 2026Market cap $22.22MP/E –Yield –
Celularity ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Celularity's ebitda for the twelve months ending Jun 30, 2026 was -$42.57M. For fiscal 2025 it was -$54.01M. The highest annual figure on record is -$16.16M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$54.01M | – |
| FY2024 | Dec 31, 2024 | -$30.44M | – |
| FY2023 | Dec 31, 2023 | -$182.96M | – |
| FY2022 | Dec 31, 2022 | -$16.16M | – |
| FY2021 | Dec 31, 2021 | -$100.24M | – |
| FY2020 | Dec 31, 2020 | -$143.75M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.70M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.54M | – |
| Q4 FY2025 | Dec 31, 2025 | -$20.26M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.08M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.65M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.40M | -147.4% |
| Q3 FY2024 | Sep 30, 2024 | -$10.01M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.64M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.22M | – |
| Q4 FY2023 | Dec 31, 2023 | $15.61M | -21.6% |
| Q3 FY2023 | Sep 30, 2023 | -$97.47M | – |
| Q2 FY2023 | Jun 30, 2023 | -$40.70M | -784.3% |
| Q1 FY2023 | Mar 31, 2023 | -$61.51M | – |
| Q4 FY2022 | Dec 31, 2022 | $19.92M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.81M | -130.0% |
| Q2 FY2022 | Jun 30, 2022 | $5.95M | – |
| Q1 FY2022 | Mar 31, 2022 | -$39.33M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.35M | -195.8% |
| Q3 FY2021 | Sep 30, 2021 | $12.69M | – |
| Q2 FY2021 | Jun 30, 2021 | -$59.23M | – |
| Q1 FY2021 | Mar 31, 2021 | -$42.46M | – |
| Q4 FY2020 | Dec 31, 2020 | $12.89M | – |
See a number that looks wrong?